Floatz logo

LYSINE

NETs

ITM Solucin GmbHSmall moleculePhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
81/ 100

Competitive context

12 Active assets in the NETs cohort.

Asset / SponsorPhaseRating
DOTATOC
ITM Solucin GmbH
Phase 2B
ARG
ITM Solucin GmbH
Phase 1CC
LIDOCAINE
Fudan University
N/AD
Rocuronium
Fudan University
N/AD
Oxycodone
Fudan University
N/AD

View all 12 →

Same molecule, other indications

LYSINE is also rated in:

Neuroendocrine TumorsDormant
B
Indicative ·
59 / 100
View asset →
major depressive disorderDormant
CCC
Indicative ·
53 / 100
View asset →
Metastatic Neuroendocrine Prostate CancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →